PharmGen Science Inc (004720) — Working Capital to Net Assets Ratio
PharmGen Science Inc (004720) has a Working Capital to Net Assets ratio of 21.0% as of September 2025. Working capital of ₩52.14 Billion (current assets of ₩93.89 Billion minus current liabilities of ₩41.75 Billion) is measured against net assets of ₩247.76 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 004720 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
PharmGen Science Inc Working Capital to Net Assets (2013–2024)
This chart shows how PharmGen Science Inc's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 21.0%, reflecting working capital of ₩52.14 Billion against net assets of ₩247.76 Billion KRW. See operational self-sufficiency of PharmGen Science Inc to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for PharmGen Science Inc (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for PharmGen Science Inc from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see PharmGen Science Inc (004720) market capitalisation.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 18.2% | ₩45.29 Billion | ₩249.43 Billion | ₩110.71 Billion | ₩65.42 Billion | ▲ +4.1 pp |
| 2023 | 14.1% | ₩32.16 Billion | ₩228.21 Billion | ₩95.33 Billion | ₩63.17 Billion | ▲ +13.0 pp |
| 2022 | 1.1% | ₩2.36 Billion | ₩207.12 Billion | ₩70.54 Billion | ₩68.19 Billion | ▼ -3.8 pp |
| 2021 | 4.9% | ₩6.26 Billion | ₩126.93 Billion | ₩77.38 Billion | ₩71.12 Billion | ▼ -39.6 pp |
| 2020 | 44.5% | ₩37.21 Billion | ₩83.57 Billion | ₩74.90 Billion | ₩37.69 Billion | ▲ +8.5 pp |
| 2019 | 36.0% | ₩20.28 Billion | ₩56.25 Billion | ₩50.62 Billion | ₩30.34 Billion | ▼ -48.4 pp |
| 2018 | 84.4% | ₩47.99 Billion | ₩56.85 Billion | ₩80.95 Billion | ₩32.97 Billion | ▼ -4.2 pp |
| 2017 | 88.6% | ₩45.24 Billion | ₩51.05 Billion | ₩55.32 Billion | ₩10.09 Billion | ▲ +2.8 pp |
| 2016 | 85.8% | ₩31.23 Billion | ₩36.41 Billion | ₩53.09 Billion | ₩21.85 Billion | ▼ -2.8 pp |
| 2015 | 88.6% | ₩25.39 Billion | ₩28.66 Billion | ₩38.20 Billion | ₩12.80 Billion | ▲ +8.5 pp |
| 2014 | 80.1% | ₩16.11 Billion | ₩20.12 Billion | ₩33.79 Billion | ₩17.68 Billion | ▲ +2.0 pp |
| 2013 | 78.2% | ₩18.63 Billion | ₩23.83 Billion | ₩30.68 Billion | ₩12.05 Billion | — |